• Ginkgo Bioworks Holdings Inc DNA.N reported a quarterly adjusted loss of $2.00​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-4.40. The mean expectation of five analysts for the quarter was for a loss of $1.77 per share. Wall Street expected results to range from $-2.57 to $-1.30 per share.

• Revenue rose 26.2% to $43.85 million from a year ago; analysts expected $44.46 million.

• Ginkgo Bioworks Holdings Inc's reported EPS for the quarter was a loss of $2.00​.

• The company reported a quarterly loss of $107.53 million.

• Ginkgo Bioworks Holdings Inc shares had risen by 6.5% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "sell" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and 4 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "sell"

Wall Street's median 12-month price target for Ginkgo Bioworks Holdings Inc is $8.00

This summary was machine generated from LSEG data February 26 at 12:01 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)